{"filing":{"accession_number":"0001171843-26-006203","cik":"0001771885","ticker":"QNTM","company_name":"Quantum Biopharma Ltd.","form":"6-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"f6k_092426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1771885/000117184326006203/f6k_092426.htm"},"events":[{"id":34741,"run_id":31987,"accession_number":"0001171843-26-006203","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The press release announces the appointment of Michael Zapolin (\"Zappy\") as CEO of Unbuzzd Wellness Inc., Quantum BioPharma's licensee in which Quantum retains 19.48% ownership and receives royalty payments. The appointment is material because Zapolin's mandate includes financing, listing Unbuzzd on a stock exchange, and executing nationwide commercial rollout—strategic milestones directly affecting Quantum's financial interests and royalty stream. The disclosure also notes the departure of prior CEO Richard Buzbuzian, but the principal disclosed action is Zapolin's appointment to lead the company forward.","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-09-24","form":"6-K","submitted_at":null,"items":[{"id":38570,"accession_number":"0001171843-26-006203","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The press release announces the appointment of Michael Zapolin (\"Zappy\") as CEO of Unbuzzd Wellness Inc., Quantum BioPharma's licensee in which Quantum retains 19.48% ownership and receives royalty payments. The appointment is material because Zapolin's mandate includes financing, listing Unbuzzd on a stock exchange, and executing nationwide commercial rollout—strategic milestones directly affecting Quantum's financial interests and royalty stream. The disclosure also notes the departure of prior CEO Richard Buzbuzian, but the principal disclosed action is Zapolin's appointment to lead the company forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:01:56.146093+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38570,"accession_number":"0001171843-26-006203","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The press release announces the appointment of Michael Zapolin (\"Zappy\") as CEO of Unbuzzd Wellness Inc., Quantum BioPharma's licensee in which Quantum retains 19.48% ownership and receives royalty payments. The appointment is material because Zapolin's mandate includes financing, listing Unbuzzd on a stock exchange, and executing nationwide commercial rollout—strategic milestones directly affecting Quantum's financial interests and royalty stream. The disclosure also notes the departure of prior CEO Richard Buzbuzian, but the principal disclosed action is Zapolin's appointment to lead the company forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:01:56.146093+00:00","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-09-24"}]}